Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0 - PubMed
6 hours ago
- #Renal Cell Carcinoma
- #Clinical Guidelines
- #Immunotherapy
- Immunotherapy has been a key treatment for renal cell carcinoma (RCC) for over 30 years.
- Early immunotherapies like interleukin 2 and interferon-alpha showed limited success with only a small number of complete responses.
- Immune checkpoint inhibitors (ICIs) have improved response rates and survival, transforming first-line and subsequent-line treatments.
- ICIs are now being used in adjuvant settings for high-risk RCC patients.
- The Society for Immunotherapy of Cancer (SITC) developed clinical practice guidelines to address patient selection, histology, risk considerations, and integration with local therapies.
- The guidelines provide recommendations on therapy selection in adjuvant and metastatic settings, special patient populations, response monitoring, and patient education.
- The goal is to improve patient care by offering evidence-based and consensus-based guidance to the oncology community.